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ABSTRACT Spinal muscular atrophy (SMA) is caused by homozygous mutations in human SMN1. Expression of a duplicate gene (SMN2) primarily results in skipping of exon 7 and
production of an unstable protein isoform, SMNΔ7. Although SMN2 exon skipping is the
principal contributor to SMA severity, mechanisms governing stability of survival motor
neuron (SMN) isoforms are poorly understood. We used a Drosophila model system and
label-free proteomics to identify the SCFSlmb ubiquitin E3 ligase complex as a novel SMN
binding partner. SCFSlmb interacts with a phosphor degron embedded within the human and
fruitfly SMN YG-box oligomerization domains. Substitution of a conserved serine (S270A)
interferes with SCFSlmb binding and stabilizes SMNΔ7. SMA-causing missense mutations that
block multimerization of full-length SMN are also stabilized in the degron mutant background. Overexpression of SMNΔ7S270A, but not wild-type (WT) SMNΔ7, provides a protective effect in SMA model mice and human motor neuron cell culture systems. Our findings
support a model wherein the degron is exposed when SMN is monomeric and sequestered
when SMN forms higher-order multimers.
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INTRODUCTION
Spinal muscular atrophy (SMA) is a common neuromuscular disorder, recognized as the most prevalent genetic cause of early childhood mortality (Pearn, 1980). Patients with the most severe form of
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Cullin1; iPSC, induced pluripotent stem cells; NMJ, neuromuscular junction; S2,
Schneider 2; SkpA, Skp1-related A; Slmb, supernumerary limbs; SMA, spinal muscular atrophy; SMN, survival motor neuron; UPS, ubiquitin proteasome system.
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the disease, which is also the most common, become symptomatic
in the first 6 mo of life and rarely live past 2 yr (Prior, 2010; Wee
et al., 2010). Because the onset of symptoms and their severity can
vary, SMA has historically been classified into three subtypes (Ogino
and Wilson, 2004). More recently, clinicians have recognized that
SMA is better characterized as a continuous spectrum disorder,
ranging from acute (prenatal onset) to nearly asymptomatic (Tiziano
et al., 2013). Clinically, SMA patients experience degeneration of
motor neurons in the anterior horn of the lower spinal cord (Crawford
and Pardo, 1996). This leads to progressive atrophy of proximal
muscle groups, ultimately resulting in loss of motor function and
symmetrical paralysis. The cause of death is often restrictive respiratory failure (Kolb and Kissell, 2015).
SMA typically results from homozygous deletion of the survival
motor neuron 1 (SMN1) gene (Lefebvre et al., 1995). A small fraction
Molecular Biology of the Cell

of SMA patients have lost one copy of SMN1 and the remaining
copy contains a point mutation (Burghes and Beattie, 2009). Humans
have two SMN paralogues, named SMN1 and SMN2, both of which
contribute to total cellular levels of survival motor neuron (SMN)
protein. SMN2 exon 7 contains a silent base change that alters splicing to primarily produce a truncated, unstable protein product
called SMN∆7 (Lorson et al., 1999; Monani et al., 1999; Lorson and
Androphy, 2000). The last 16 amino acids of SMN are replaced in
SMNΔ7 by four amino acids, EMLA, encoded by exon 8. Current
estimates suggest that SMN2 produces 10–15% of the level of fulllength protein produced by SMN1 (Lorson et al., 2010). Complete
loss of SMN is lethal in all organisms investigated to date (O’Hearn
et al., 2016). Although the amount of full-length protein produced
by SMN2 is not enough to compensate for loss of SMN1, SMN2 is
sufficient to rescue embryonic lethality (Monani et al., 2000). SMA is
therefore a disease that arises due to a hypomorphic reduction in
SMN levels (Lefebvre et al., 1995). Furthermore, relative levels of
the SMN protein correlate with the phenotypic severity of SMA
(Coovert et al., 1997; Lefebvre et al., 1997).
Whereas a causative link between SMN1 and SMA was established in the early 1990s, the molecular role of SMN in disease etiology remains unclear. SMN is the central component of a multimeric
protein assemblage known as the SMN complex (Li et al., 2014;
Matera and Wang, 2014). The best-characterized function of this
complex, which is found in all tissues of metazoan organisms, is in
the cytoplasmic assembly of small nuclear ribonucleoproteins
(snRNPs), core components of the spliceosome (Fischer et al., 1997;
Meister et al., 2001; Pellizzoni et al., 2002).
Although it is ubiquitously expressed, SMN has also been implicated in a number of tissue-specific processes related to neurons
and muscles. These functions include actin dynamics (Oprea et al.,
2008; Ackermann et al., 2013), axonal pathfinding (Fan and Simard,
2002; McWhorter et al., 2003; Sharma et al., 2005), axonal transport
of β-actin mRNP (Rossoll et al., 2003), phosphatase and tensin homolog-mediated (PTEN-mediated) protein synthesis pathways
(Ning et al., 2010), translational regulation (Sanchez et al., 2013),
neuromuscular junction formation and function (Chan et al., 2003;
Kariya et al., 2008; Kong et al., 2009; Voigt et al., 2010), myoblast
fusion (Shafey et al., 2005), and maintenance of muscle architecture
(Rajendra et al., 2007; Walker et al., 2008; Bowerman et al., 2009).
Ubiquitylation pathways have been shown to regulate the stability and degradation of SMN (Chang et al., 2004; Burnett et al., 2009;
Hsu et al., 2010) as well as axonal and synaptic stability (Korhonen
and Lindholm, 2004). In the ubiquitin proteasome system (UPS),
proteins destined for degradation are tagged by linkage to ubiquitin through the action of three factors (Petroski, 2008). E1 proteins
activate ubiquitin and transfer it to the E2 enzyme. E2 proteins
conjugate ubiquitin to their substrates. E3 proteins recognize the
substrate and assist in the transfer of ubiquitin from the E2. Because
E3 ligases confer substrate specificity, they are typically considered
as candidates for targeted inhibition of protein degradation. Ubiquitin homeostasis is thought to be particularly important for neuromuscular pathology in SMA (Groen and Gillingwater, 2015). Indeed,
mouse models of SMA display widespread perturbations in UBA1
(ubiquitin-like modifier activating enzyme 1) levels (Wishart et al.,
2014). Furthermore, mutations in UBA1 are known to cause X-linked
infantile SMA (Ramser et al., 2008; Schmutzler et al., 2008).
Given the importance of these processes to normal development as well as neurodegenerative disease, we set out to identify
and characterize novel SMN binding partners. Previously, we developed Drosophila melanogaster as a model system wherein the endogenous Smn gene is replaced with a Flag-Smn transgene (Praveen
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et al., 2012). Although it is highly similar to human SMN1 and SMN2,
the entire open reading frame of fruitfly Smn is contained within a
single exon, and so only full-length SMN protein is expressed in
Drosophila (Rajendra et al., 2007). When modeled in the fly, SMAcausing point mutations recapitulate the full range of phenotypic
severity seen in humans (Praveen et al., 2014; Garcia et al., 2016).
Using this system, we carried out proteomic profiling of Flag-purified
embryonic lysates and identified the SCFSlmb E3 ubiquitin ligase
complex as a novel SMN interactor. Importantly, this interaction
is conserved from flies to humans. We show that SCFSlmb binding
requires a phosphodegron motif located within the SMN self-oligomerization domain, mutation of which stabilizes SMN∆7 and, to a
lesser extent, full-length SMN. Additional studies in flies, mice, and
human cells elucidate a disease-relevant mechanism whereby
SMN protein stability is regulated by self-oligomerization. Other E3
ligases have been reported to target SMN for degradation in
cultured human cells (Hsu et al., 2010; Kwon et al., 2013; Han et al.,
2016). Given our findings in fruit-fly embryos, SMN is likely targeted
by multiple E3 ubiquitin ligases.

RESULTS
Flag-SMN interacts with ubiquitin proteasome system
proteins
We previously generated transgenic flies that express Flag-tagged
SMN proteins in an otherwise null Smn background (Praveen et al.,
2012). To preserve endogenous expression patterns, the constructs
are driven by the native promoter and flanking sequences. As described under Materials and Methods, we intercrossed hemizygous
Flag-SmnWT,SmnX7/SmnD animals to establish a stock wherein all of
the SMN protein, including the maternal contribution, is epitope
tagged. After breeding them for >100 generations, essentially all of
the animals are homozygous for the Flag-SmnWT transgene, but
second-site recessive mutations are minimized due to the use of two
different Smn null alleles. Adults from this stock display no apparent
defects and have an eclosion frequency (∼90%) similar to that of
wild-type (Oregon-R) animals.
We collected (0–12 h) embryos from Flag-SmnWT/WT,SmnX7/D
(SMN) and Oregon-R (Ctrl) animals and analyzed Flag-purified
lysates by “label-free” mass spectrometry. In addition to Flag-SMN,
we identified SMN complex components Gemin2 and Gemin3,
along with all seven of the canonical Sm-core snRNP proteins (Figure
1A). We also identified the U7-specific Sm-like heterodimer
Lsm10/11 (Pillai et al., 2003) and the Gemin5 orthologue, Rigor
mortis (Gates et al., 2004). Previous studies of Schneider2 (S2) cells
transfected with epitope-tagged Smn had identified most of the
proteins listed above as SMN binding partners in Drosophila (Kroiss
et al., 2008). However, despite bioinformatic and cell biological data
indicating that Rigor mortis is part of the fruit-fly SMN complex, this
protein failed to copurify with SMN in S2 cells (Kroiss et al., 2008;
Cauchi et al., 2010; Guruharsha et al., 2011). On the basis of our
purification data, we conclude that the conditions are effective and
that Rigor mortis/Gemin5 is an integral member of the SMN
complex in flies.
A detailed proteomic analysis of these flies will be presented
elsewhere. As shown in Figure 1B, our preliminary analysis identified
396 proteins, 114 of which were detected only in the Flag-SMN
sample and not in the control. An additional 279 proteins were detected in both the Flag purification and control samples. In addition
to SMN complex members, we copurified numerous factors that are
part of the ubiquitin proteasome system (UPS; Figure 1C). Among
these UPS proteins, we identified Cullin 1 (Cul1), Skp1-related A
(SkpA), and supernumerary limbs (Slmb), as being highly enriched
SCFSlmb mediates degradation of SMN
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1998). SkpA is a bridging protein essential
for interaction of Cul1 with the F-box protein (Patton et al., 1998a,b). Because of its
role in substrate recognition, Slmb is likely
to be the direct interacting partner of SMN
within the SCFSlmb complex. For this reason,
we focused on Slmb for the initial validation.
As shown, Slmb was easily detectable in
Flag-purified eluates from embryos expressing Flag-SMN and nearly undetectable in
those from control embryos (Figure 1D).
SmB and SmD3 were also easily detectable
by Western blot in Flag-purified embryonic
lysates and were used as positive controls
for known protein interaction partners of
SMN. Tubulin and α-actinin were not detected as interacting with SMN in our purification and demonstrate the specificity of
the detected SMN interactions.

SCFSlmb is a bona fide SMN interaction
partner that ubiquitylates SMN
As an E3 ubiquitin ligase, the SCFSlmb complex is a substrate recognition component
of the ubiquitin proteasome system. As outlined in Figure 2A, E3 ligases work with E1
and E2 proteins to ubiquitylate their targets.
The interaction of SCFSlmb with SMN was
verified in a reciprocal coimmunoprecipitation, demonstrating that Flag-tagged SCF
components form complexes with endogenous SMN (Figure 2B) in S2 cells.
SCF complexes are highly conserved
from flies to humans: SkpA is 77% identical
to human Skp1, Cul1 is 63% identical, and
Slmb is 80% identical to its human homologues, B-TrCP1 and B-TrCP2. Slmb/B-TrCP
is the SCF component that directly contacts
substrates of the E3 ligase. We therefore
tested the interaction of recombinant human SMN in complex with (SMN•Gem2)
FIGURE 1: Flag-SMN immunopurified lysates contain known protein interaction partners and
Gupta
et al., 2015) with glutathione S-transubiquitin proteasome system (UPS) proteins. (A) Lysates from Oregon-R control (Ctrl) Drosophila
ferase (GST)-tagged B-TrCP1 and -SMN
embryos and embryos expressing only transgenic Flag-SMN (SMN) were Flag-immunopurified,
proteins in an in vitro binding assay. As
and protein eluates were separated by gel electrophoresis and silver stained. Band identities
shown in Figure 2C, SMN•Gem2 did not inpredicted by size using information from panels C and D. (B) Direct mass spectrometric analysis
teract with GST alone but was detected at
of the eluates (which were not gel purified) identified a total of 396 proteins, 114 of which were
detected only in SMN sample and 279 of which were detected in both SMN and Ctrl samples.
high levels following pull down with either
(C) Flag-purified eluates were analyzed by “label-free” mass spectrometry. Numerous proteins
GST-SMN (positive control) or GST-B-TrCP1.
that copurify with Flag-SMN are part of the ubiquitin proteasome system (UPS). Of these UPS
We also tested the interaction of Flagproteins, Cullin 1 (Cul 1), SkpA, and supernumerary limbs (Slmb) were highly enriched (at least
tagged Drosophila SCF components with
10-fold) in the SMN sample as compared with Ctrl. (D) Western blot analysis of Flag-purified
endogenous human SMN in HEK 293T cells
eluates was used to further validate the presence or absence of SMN interaction partners.
(Figure 2D). Accordingly, human SMN was
Flag-SMN was successfully purified from SMN embryos but was undetectable in the control. As
positive controls for known protein interaction partners of SMN, SmB and SmD3 were also easily coprecipitated with Flag-Cul1 and FlagSlmb and at lower levels following Flagdetectable by Western blotting using anti-Sm antibodies. The presence of Slmb was verified
SkpA immunoprecipitation. Flag-B-TrCP1
using anti-Slmb. α-Actinin and tubulin were not enriched in our purification and are used as
and Flag-B-TrCP2, the two human homonegative controls to demonstrate specificity.
logues of Slmb, also copurified with endogenous human SMN in HEK 293T cells (Figure 2E). Altogether, these
(>10-fold) in Flag-SMN samples as compared with the control. Todata demonstrate a conserved interaction between SMN and the
gether, these proteins comprise the SCFSlmb E3 ubiquitin ligase.
SCFSlmb/B-TrCP E3 ubiquitin ligase complex.
Cul1 forms the major structural scaffold of this horseshoe-shaped,
To test the functional consequences of this conserved interaction
multisubunit complex (Zheng et al., 2002). Slmb is an F-box protein
between SMN and SCFSlmb/B-TrCP, a cell-based ubiquitylation assay
and is the substrate recognition component (Jiang and Struhl,
98 | K. M. Gray et al.
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FIGURE 2: Conserved interaction between SMN and the SCFSlmb/B-TrCP E3 ubiquitin ligase results in ubiquitylation of
SMN. (A) E3 ligases work with E1 and E2 proteins to ubiquitylate their targets. The SCFSlmb/B-TrCP E3 ubiquitin ligase is
made up of three proteins: Cul1, SkpA, and Slmb. The E3 ubiquitin ligase is the substrate recognition component of
the ubiquitin proteasome system. (B) Following Cul1-Flag, SkpA-Flag, Flag-Slmb, and Flag-Gem2 immunoprecipitation
from Drosophila S2 cell lysates, Western analysis using anti-SMN antibody for endogenous SMN was carried out.
Copurification of each of the SCF components with endogenous SMN was detected. (C) An in vitro binding assay tested
direct interaction between human SMNΔ5-Gemin2 (SMN•Gem2) (Martin et al., 2012; Gupta et al., 2015) and purified
GST-tagged proteins. SMN•Gem2 did not interact with GST protein alone but bound to GST tagged Drosophila SMN
(GST-SMN) and GST tagged human B-TrCP1 (GST-B-TrCP1). Levels of GST alone, GST-SMN, and GST-B-TrCP1 were
detected using anti-GST antibody. (D) The interaction of Flag-tagged Drosophila SCF components with endogenous
human SMN was tested in in HEK 293T cells. Human SMN was detected at high levels following immunoprecipitation of
Drosophila Flag-Cul1 and Flag-Slmb and detected at a lower level following Drosophila Flag-SkpA immunoprecipitation.
(E) Flag-tagged versions of the human homologues of Slmb, Flag-B-TrCP1, and Flag-B-TrCP2, interact with endogenous
human SMN in HEK 293T cells demonstrated by Flag-immunopurification followed by immunodetection of SMN.
(F) Protein lysate from HEK 293T cells transfected with 6xHis-Flag-ubiquitin (6HF-Ub) and GFP-SMN was purified using a
Ni2+ pull down for the tagged ubiquitin. Baseline levels of ubiquitylated GFP-SMN were detected using anti-GFP
antibody. Following transfection of Flag-B-TrCP1 or Flag-B-TrCP2, the levels of ubiquitylated SMN markedly increased.
Ubiquitylation levels were further increased following addition of both proteins together. In the input, GFP-SMN was
detected using anti-GFP antibody, Flag-B-TrCP1 and Flag-B-TrCP2 were detected using anti-Flag antibody, and GAPDH
was detected by anti-GAPDH antibody. In the Ni2+ pull down, ubiquitylated GFP-SMN was detected using anti-GFP
antibody and 6HF-Ub was detected using anti-Flag antibody to verify successful pull down of tagged ubiquitin.
Volume 29 January 15, 2018
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was performed (Figure 2F). Protein lysate from HEK 293T cells transfected with 6xHis-Flag-ubiquitin and GFP-SMN was purified using a
Ni2+ pull down for the tagged ubiquitin. Baseline levels of ubiquitylated GFP-SMN were detected using anti-GFP antibody. Following
transfection of Flag-B-TrCP1 or Flag-B-TrCP2, the levels of ubiquitylated SMN markedly increased (Figure 2F). Ubiquitylation levels
were further increased following addition of both proteins together.

These experiments demonstrate that SCFSlmb/B-TrCP can ubiquitylate
SMN in vivo.

Depletion of Slmb/B-TrCP results in a modest increase in
SMN levels
Given that one of the primary functions of protein ubiquitylation is
to target proteins to the proteasome, we examined whether depletion of Slmb by RNA interference (RNAi) using double-stranded RNA (dsRNA) in S2
cells would increase SMN levels (Figure 3A).
Following Slmb RNAi, endogenous SMN
levels were modestly increased as compared with cells treated with control dsRNA.
We obtained similar results using an siRNA
that targets both B-TrCP1 and B-TrCP2 in
HeLa cells. As shown in Figure 3B, we detected a modest increase in levels of fulllength SMN following B-TrCP RNAi but not
control RNAi. Next, we treated S2 cells with
cycloheximide (CHX), in the presence or absence of dsRNA targeting Slmb, to determine whether differences in SMN levels
would be exacerbated when production of
new proteins was prevented (Figure 3C).
SMN protein levels were also specifically
targeted using dsRNA against Smn as a
positive control for the RNAi treatment. At 6
h post–CHX treatment, there was a modest
increase in full-length SMN levels following
Slmb RNAi as compared with the initial
timepoint (0 h) or the negative control (Ctrl)
RNAi (Figure 3C). Together, these data indicate that Slmb/B-TrCP participates in the
regulation of SMN protein levels.

Identification and characterization of a
Slmb/B-TrCP degradation signal in SMN

FIGURE 3: Depletion of Slmb/B-TrCP results in an increase of SMN levels. (A) Depletion of Slmb
using 10-d (10d) treatment with dsRNA in Drosophila S2 cells resulted in modestly increased
SMN levels. Following Slmb RNAi, full-length SMN levels were increased as compared with
cells treated with control dsRNA against Gaussia Luciferase, which is not expressed in S2 cells.
(B) The effect of B-TrCP depletion on SMN levels in human cells was tested using siRNA that
targets both B-TrCP1 and B-TrCP2 in HeLa cells. We detected a modest increase in levels of
full-length endogenous SMN after B-TrCP RNAi but not control (scramble) RNAi. (C) Drosophila
S2 cells were treated with cycloheximide (CHX), an inhibitor of protein synthesis, following Slmb
depletion following a 3-d dsRNA treatment to test whether differences in protein levels would
be exacerbated when the production of new protein was prevented. SMN protein levels were
also directly targeted using dsRNA against Smn as a positive control for the RNAi treatment.
As a negative control (Ctrl), dsRNA against oskar, which is not expressed in S2 cells, was used.
Protein was collected at 0, 2, and 6 h post–CHX treatment. At 6 h post–CHX treatment, there is
a modest increase in full-length SMN levels following Slmb RNAi as compared with the initial
time point (0 h) and as compared with control RNAi treatment.
100 | K. M. Gray et al.

Studies of numerous UPS substrates in a variety of species have revealed the presence of
degradation signals (called degrons) that are
required for proper E3 target recognition
and binding. Slmb/B-TrCP canonically recognizes a consensus DpSGXXpS/T degron,
where p indicates a phosphoryl group (Fuchs
et al., 2004; Jin et al., 2005; Frescas and
Pagano, 2008). There are also several known
variants of this motif, for example, DDGFVD,
SSGYFS, and TSGCSS (Kim et al., 2015). As
shown in Figure 4A, we identified a putative
Slmb/B-TrCP degron (269MSGYHT274) in the
highly conserved self-oligomerization domain (YG Box) of human SMN. Interestingly,
this sequence was previously identified as
part of a larger degron motif (268YMSGYHTGYYMEMLA282) that was thought to be
created in SMN∆7 by SMN2 alternative splicing (Cho and Dreyfuss, 2010). In particular,
mutation of S270 (S201 in flies) to alanine
was shown to dramatically stabilize SMN∆7
constructs in human cells, and overexpression of SMN∆7S270A in SMN-deficient
chicken DT40 cells rescued their viability
Molecular Biology of the Cell

FIGURE 4: Identification and mutation of a putative Slmb/B-TrCP phosphodegron
(A) Identification of a conserved putative Slmb phosphodegron (DpSGXXpS/T motif variant) in
the C-terminal self-oligomerization domain (YG Box) of SMN. The amino acid sequence of SMN
from a variety of vertebrates is shown to illustrate conservation of this motif and rationale for
the amino acid changes. Full-length human SMN is labeled as “Human,” and the truncated
isoform is labeled “hSMNΔ7.” Endogenous D. melanogaster SMN is labeled “Fruitfly.” To
generate a more vertebrate-like SMN, key amino acids in Drosophila SMN were changed to
amino acids conserved in vertebrates. Using this SMN backbone, a serine-to-alanine mutation
was made in the putative degron in both full-length (vSMNS201A) and truncated SMNΔ7
(vSMNΔ7A). An additional SMN construct that is the same length as SMNΔ7, but has the amino
acid sequence GLRQ (the next amino acids in the sequence) rather than EMLA (the amino acids
introduced by mis-splicing of SMN2), was generated. The same serine to alanine mutation was
made in this construct as well (MGLRQ* and MGLRQ*S201A). Finally, to mimic a phosphorylated
serine, a full-length vSmnS201D and truncated vSmnΔ7D were also employed. (B) Western blotting
was used to determine protein levels of each of these SMN constructs, with expression driven
by the endogenous promoter, in Drosophila S2 cells. Both the vSMN and vSMNΔ7S proteins
show increased levels when the serine is mutated to an alanine, indicating disruption of the
normal degradation of SMN. Additionally, MGLRQ* protein is present at higher levels than is
vSMNΔ7S and protein levels do not change when the serine is mutated to an alanine.
Normalized fold change as compared with vSmn levels is indicated at the bottom. *p < 0.05,
**p < 0.01, n = 3. (C) Flag-tagged SMN constructs were cotransfected with Myc-Slmb in
Drosophila S2 cells. Protein lysates were Flag-immunoprecipitated and probed with anti-Myc
antibody to detect SMN-Slmb interaction. In both full-length SMN (vSMN) and truncated SMN
(vSMNΔ7), serine-to-alanine mutation decreased interaction of Slmb with SMN. Truncated SMN
(vSMNΔ7) showed a dramatically increased interaction with Slmb as compared with full-length
SMN (vSMN), despite the fact it is present at lower levels. (D) Full-length SMN constructs
containing point mutations known to decrease self-oligomerization (SmnY203C and SmnG206S) and
a mutation that does not disrupt self-oligomerization in the fly (SmnG210V) with and without the
Volume 29 January 15, 2018

(Cho and Dreyfuss, 2010). However, factors
responsible for specifically mediating SMN∆7
degradation have not been identified.
To develop a more disease-relevant
Drosophila system to investigate SMN YG
box function, we generated a “vertebratelike” SMN construct, called vSmn (Figure
4A). Transgenic flies expressing Flag-vSmn
and Flag-vSmnS201A in the background of an
SmnX7 null mutation are fully viable (Supplemental Figure S1). In fact, the eclosion
frequencies of these animals are consistently higher than those that express FlagSmnWT (Supplemental Figure S1). Additional
Smn mutant constructs were generated using the vSmn backbone, including both the
full-length (e.g., vSmnS201A) and truncated
(e.g., vSmnΔ7A) versions of the protein
(Figure 4A). To test the effects of overall
protein length and distance of the putative
degron from the C-terminus, we also generated vSmn constructs that are the same
length as SMNΔ7, replacing the MEMLA*
motif (the amino acids introduced by human
SMN2 splicing) with MGLRQ*; see Figure
4A. The S201A mutation was created in this
construct as well (MGLRQ*S201A). To mimic a
constitutively phosphorylated state, we also
introduced serine to aspartate mutations,
vSmnS201D and vSmn∆7D. We transfected
each of these constructs, Flag-tagged and
driven by the native Smn promoter, into S2
cells and measured protein levels by Western blotting (Figure 4B). We note that these
constructs are expressed at levels far below
those of endogenous SMN protein in S2
cells; moreover, they do not affect levels of
endogenous SMN (Supplemental Figure
S2). As shown, the vSmnS201A and vSMNΔ7A
constructs exhibited increased protein levels compared with their serine containing
counterparts, whereas levels of the S201D
mutants were reduced, suggesting that the
phosphodegron motif identified in human
SMN∆7 (Cho and Dreyfuss, 2010) is also
conserved in the fly protein. In addition to
examining protein levels of each of these
constructs in cell culture, transgenic flies expressing vSmn, vSmnS201A, vSmnΔ7S, and
vSmnΔ7A were created. Here again, we observed that the S201A mutation increased
protein levels of both full-length SMN and
SMN∆7 (Supplemental Figure S3).

serine-to-alanine mutation were transfected
in Drosophila S2 cells. The constructs
containing the serine to alanine mutation
are as follows: SmnY203C→Smn3C-1A,
SmnG206S→Smn6S-1A, SmnG210V→Smn10V-1A. The
serine to alanine mutation has a stabilizing
effect on SMN mutants with poor selfoligomerization capability. *p < 0.05, n = 3.
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The MGLRQ* construct is present at levels that are similar to wild
type (vSmn) and much higher than vSmnΔ7S. Based on the crystal
structures of the SMN YG box (Martin et al., 2012; Gupta et al.,
2015), the presence of the MGLR insertion in Drosophila SMN is
predicted to promote self-oligomerization (unpublished data), thus
stabilizing the protein within the SMN complex (Burnett et al., 2009).
By the same logic, the relative inability of vSmnΔ7S to self-interact
would be predicted to lead to its destruction. To determine whether
the observed increase in SMN protein levels correlated with its
ability to interact with Slmb, we cotransfected the appropriate
Flag-Smn constructs with Myc-Slmb in S2 cells. Protein lysates were
then Flag-immunoprecipitated and probed with anti-Myc antibody
(Figure 4C). The S201A mutation decreased binding of Slmb to both
the full-length and the truncated SMN isoforms (Figure 4C). However, the vSmn∆7S construct coprecipitated the greatest amount
of Slmb protein, despite the fact that it is present at much lower
levels in the input lysate (Figure 4C). Because SMN∆7 is defective in
self-interaction, this result suggests that the degron is more accessible to Slmb when SMN is monomeric and cannot efficiently
oligomerize.

SMN self-oligomerization regulates access to the Slmb
degron
To examine the connection between SMN self-oligomerization and
degron accessibility more closely, we took advantage of two SMA
patient-derived point mutations (Y203C and G206S) that are known
to destabilize the full-length protein and to decrease its selfoligomerization capacity (Praveen et al., 2014). As a control, we also
employed an SMA-causing mutation (G210V) that does not disrupt
SMN self-oligomerization (Praveen et al., 2014; Gupta et al., 2015).
Next, we introduced the S201A degron mutation into all three of
these full-length SMN constructs, transfected them into S2 cells and
carried out Western blotting (Figure 4D and Supplemental Figure
S2). The S201A degron mutation has a clear stabilizing effect on the
G206S and Y203C constructs, as compared with the effect of S201A
paired with G210V. Hence, we conclude that the Slmb degron is
exposed when SMN is present predominantly as a monomer,
whereas it is less accessible when the protein is able to form higherorder multimers.

Mutation of the Slmb degron rescues viability and
locomotion defects in SMA model flies
FIGURE 5: Mutation of the Slmb degron rescues defects in SMA
model flies. (A) Viability analysis of an SMA point mutation (G206S) in
the presence and absence of the degron mutation, S201A. Flies with
the following genotypes were analyzed in this experiment: Oregon-R
(Ctrl), Flag-SmnWT,SmnX7/SmnX7 (SmnWT), Flag-SmnG206S,SmnX7/SmnX7
(SmnG206S), Flag-SmnG206,S201A,SmnX7/SmnX7 (Smn6S-1A), or SmnX7/SmnX7
(SmnX7). The data for each genotype are expressed as a fraction of
pupae or adults over the total number of starting larvae, n = 200.
Expression of the WT transgene (SmnWT) shows robust rescue of the
null (SmnX7) phenotype (∼68% adults). SmnG206S is a larval lethal
mutation. In two independent recombinant lines of Smn6S-1A (Smn6S-1A1
and Smn6S-1A2) a fraction of the larvae complete development to
become adults. (B) Locomotor ability of early third-instar larvae was
determined by tracking their movement for 1 min and then calculating
the velocity. To account for potential differences in larval size, speed is
expressed as average body lengths per second moved. Genotypes
are as in panel A. SmnG206S larvae move similarly to null animals. The
motility of Smn6S-1A1 and Smn6S-1A2 larvae is not different from Ctrl or
SmnWT larvae. ***p < 0.001, n = 50–60 larvae. (C) Larval protein levels
were examined by Western blotting; genotypes as in panel A. Lysates
from hemizygous mutant lines were probed with anti-Flag or
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Next, we examined the effect of mutating the Slmb degron in the
context of the full-length protein in vivo. We characterized adult
viability, larval locomotion, and SMN protein expression phenotypes of the G206S mutants in the presence or absence of the degron mutation, S201A (Figure 5, A–C). As described previously
(Praveen et al., 2014), SmnG206S animals express very low levels of
SMN and fail to develop beyond larval stages. In contrast, flies bearing the S201A degron mutation in addition to G206S (Smn6S-1A) express markedly increased levels of SMN protein (Figure 5C), and a
good fraction of these animals complete development (Figure 5A).
Moreover, Smn6S-1A larvae display significantly improved locomotor
activity as compared with SmnG206S or SmnX7 null mutants (Figure 5B).

anti-SMN antibodies as indicated. The slower-migrating bands
represent the Flag-tagged transgenic proteins and the faster
migrating band corresponds to endogenous SMN, which is present
only in the Ctrl (note Oregon-R has two copies Smn, whereas the
transgenics have only one). SmnG206S has very low levels of SMN
protein. Flies bearing the S201A degron mutation in addition to
G206S (Smn6S-1A) express markedly increased levels of SMN protein.
Molecular Biology of the Cell

These results strongly suggest that both the structure of the G206S
mutant protein as well as its instability contribute to the organismal
phenotype.

GFP-SMN∆7 overexpression stabilizes endogenous SMN
and SMN∆7 in cultured human cells
Increased SMN2 copy number correlates with a milder clinical phenotype in SMA patients (Oskoui et al., 2016). This phenomenon was
successfully modeled in mice in the early 2000s (Hsieh-Li et al.,
2000; Monani et al., 2000), showing that high-copy-number SMN2
transgenes fully rescue the null phenotype, whereas low-copy transgenes do not. Moreover, transgenic expression of a human SMN∆7
cDNA construct in a low-copy SMN2 background improves survival
of this severe SMA mouse model from P5 (postnatal day 5) to P13
(Le et al., 2005). Although the truncated SMN likely retains partial
functionality, the protective effect of SMN∆7 overexpression may
not entirely be intrinsic to the protein. That is, SMN∆7 could also act
as a “soak-off” factor, titrating the ubiquitylation machinery and stabilizing endogenous SMN. In such a scenario, the prediction would
be that SMN∆7A is less protective than SMN∆7S because it is not a
very good substrate for SCFSlmb.
We therefore compared the stabilizing effects of overexpressing
GFP-tagged SMNΔ7S270A (SMN∆7A) and SMNΔ7 (SMN∆7S) on endogenous human SMN and SMN∆7. HEK 293T cells were transfected with equivalent amounts of GFP-SMN∆7A or -SMN∆7S. The
following day, cells were harvested after treatment with cycloheximide (CHX) for zero to 10 h. As shown in Figure 6A, Western blotting with anti-SMN showed that the SMN∆7S construct exhibits a
clear advantage over SMN∆7A in its ability to stabilize endogenous
SMN and SMN∆7. By comparing band intensities within a given
lane, we generated average intensity ratios for each time point
using replicate blots (Figure 6A, table). We then calculated a “stabilization factor” by taking a ratio of these two ratios. As shown (Figure
6A, graph), the protective benefit of overexpressing ∆7S versus ∆7A
at t = 0 h was roughly 3.0× for endogenous SMN∆7 and 1.75× for
full-length SMN. Thus, as predicted above, the GFP-SMN∆7A
construct was much less effective at stabilizing endogenous SMN
isoforms. Because SMN∆7 is a relatively good SCFSlmb substrate,
overexpression of this isoform protects full-length SMN from
degradation.
As mentioned above, experiments in an SMN-deficient chicken
DT40 cell line showed that expression of SMNΔ7A, but not SMN∆7S,
rescued cellular proliferation (Cho and Dreyfuss, 2010). These results suggest that, when stable, SMN∆7 is intrinsically functional. To
examine SMNΔ7A functionality in a more disease-relevant cell type,
control and SMA-induced pluripotent stem cell (iPSC) motor neuron
cultures were transduced with lentiviral vectors expressing an
mCherry control protein or SMNΔ7A (Figure 6B). At 4 wk postdifferentiation, no statistical difference was observed between control
and SMA motor neurons; however, by 6 wk, SMA motor neuron
numbers had decreased significantly to ∼7% of the total cell population (Figure 6B). In contrast, expression of SMNΔ7A maintained motor neuron numbers to approximately the same level as the controls
and nearly twofold greater than untreated cells (Figure 6B). Thus
expression of SMN∆7A improves survival of human iPSCs when differentiated into motor neuron lineages.

SMN∆7A is a protective modifier of intermediate SMA
mouse phenotypes
To examine the importance of the Slmb degron in a mammalian
organismal system, two previously developed SMA mouse
models were utilized. As mentioned above, the “Delta7” mouse
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(Smn−/−;SMN2;SMNΔ7) is a model of severe SMA (Le et al., 2005),
and affected pups usually die between P10 and P18 (avg. = P15).
The “2B/–“ mouse (Smn2B/–) is a model of intermediate SMA
(Bowerman et al., 2012; Rindt et al., 2015) and these animals survive
much longer, typically between P25 and P45 (avg. = P32). Adenoassociated virus serotype 9 (AAV9) was selected to deliver the SMN
cDNA isoforms to these SMA mice, as this vector has previously
been shown to enter and express in SMA-relevant tissues and can
dramatically rescue the SMA phenotype when expressing the wildtype SMN cDNA (Foust et al., 2010; Passini et al., 2010; Valori et al.,
2010; Dominguez et al., 2011; Glascock et al., 2012).
Delivery of AAV9-SMNΔ7A at P1 significantly extended survival
in the intermediate 2B/– animals, resulting in 100% of the treated
pups living beyond 100 d, similar to the results obtained with the
full-length AAV9-SMN construct (Figure 7A). In contrast, untreated
2B/– animals lived, on average, only 30 d. Mice treated with AAV9SMNΔ7S survived an average of 45 d (Figure 7A). Mice treated with
AAV9-SMNΔ7D, a phosphomimetic of the wild-type serine 270 residue, have an average life span that is equivalent or slightly shorter
than that of untreated 2B/– mice (Figure 7A). These results not only
highlight the specificity of the S270A mutation in conferring efficacy
to SMN∆7 but also illustrate that AAV9-mediated delivery of protein
alone does not improve the phenotype.
We also analyzed the effects of SMN∆7A expression in the severe Delta7 mouse model (Le et al., 2005). Treatment with AAV9SMN∆7A had only a very modest effect on Delta7 mice, as none of
the animals (treated or untreated) survived weaning (Supplemental
Figure S4). These findings are similar to the results in Drosophila.
Transgenic expression of SMN∆7A in the Smn null background is
not sufficient to rescue larval lethality (Supplemental Figure S3).
Thus expression of SMN∆7A provides a clear protective benefit to
the viability of intermediate mice but not to severe SMA models.
Consistent with the life-span data, AAV9-SMNΔ7A treated 2B/–
mice gained significantly more weight than either untreated or AAVSMNΔ7S-treated animals, nearly achieving the same weight as pups
treated with full-length AAV-SMN (Figure 7B). Treatment with fulllength SMN cDNA resulted in animals that were clearly stronger and
more mobile, consistent with the weight data (Figure 7C). Although
they did not perform as well as mice treated with full-length SMN
cDNA, the SMNΔ7A-treated animals retained strength and gross
motor function at late time points (e.g., P100), as measured by their
ability to splay their legs and maintain a hanging position using a
modified tube test, (Figure 7C). Animals treated with AAV9-SMN∆7D
and -SMN∆7S did not survive long enough for testing.

SCFSlmb primarily targets unstable SMN monomers
As indicated in Figure 8, our findings suggest a model whereby
SMN and SMN∆7 degradation is in part mediated by SCFSlmb, a
multicomponent E3 ubiquitin ligase composed of Slmb, SkpA, Cul1,
and Roc1 (Jiang and Struhl, 1998, Patton et al., 1998a,b; Zheng
et al., 2002). Our work demonstrates that B-TrCP/Slmb binds directly to SMN (Figure 2) and is one of a growing number of E3
ligases in the cell that can target SMN protein (Kwon et al., 2013;
Han et al., 2016). SMN monomers, such as those created in SMNΔ7,
are the primary targets for degradation. As shown in the model,
partially active SMN•SMN∆7 dimers and active SMN oligomers are
also substrates but to a lesser extent.

DISCUSSION
Factors that recognize the putative SMN∆7-specific degron have not
been identified, and the molecular mechanisms governing proteasomal access to SMN and SMN∆7 remain unclear. In this study, we
SCFSlmb mediates degradation of SMN
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ligase complex as a novel SMN binding partner whose interaction is conserved in human. Depletion of Slmb or B-TrCP by RNAi
resulted in an increase in steady-state SMN
levels in Drosophila and human cells, respectively. We also showed that ectopic expression of SMN∆7S270A, but not SMN∆7 or
SMN∆7S270D, a phosphomimetic, is a protective modifier of SMA phenotypes in animal
models and human iPSC cultures.

The SCFSlmb degron is exposed by
SMN2 exon skipping

FIGURE 6: Stabilization of endogenous SMN and SMNΔ7 in cultured human cells. (A) HEK 293T
cells were transfected with equivalent amounts of GFP-SMN∆7A or -SMN∆7S. The following day,
cells were harvested after treatment with cycloheximide (CHX) for zero to 10 h. Western blotting
with anti-SMN showed that SMN∆7S stabilizes endogenous SMN and SMN∆7 to a greater extent
than SMN∆7A. By comparing band intensities within a given lane, we generated average intensity
ratios for each time point using replicate blots. We then calculated a “stabilization factor” by
taking a ratio of these two ratios. The protective benefit of overexpressing ∆7S vs. ∆7A at t = 0 h
was roughly 3.0× for endogenous SMN∆7 and 1.75× for full-length SMN. (B) SMNΔ7A (S270A)
expression protects SMA iPSC-derived motor neurons. Control motor neurons were left untreated
or transduced with a lentiviral vector expressing an mCherry control. SMA motor neurons were
left untreated or transduced with a lentiviral vector expressing an mCherry control or a lentiviral
vector expressing SMNΔ7A (S270A). At 4 wk of differentiation, there was no difference in motor
neuron survival between control and SMA iPSC motor neuron cultures in any of the treatment
groups. However, at 6 wk, SMI-32-positive motor neurons showed selective loss in SMA iPSC
motor neuron cultures in the untreated and lenti-mCherry groups compared with control iPSC
motor neuron cultures. In contrast, lenti-SMNΔ7A expression fully protects SMA iPSC-derived
motor neurons. Representative images of control and SMA iPSC-derived motor neurons labeled
with SMI-32 (green) and mCherry (red). Nuclei are stained with 4’,6-diamidino-2-phenylindole
(DAPI) and shown in blue. *p < 0.05 by ANOVA. NS = not significant. n = 3

isolated factors that copurifiy with SMN from Drosophila embryos
that exclusively express Flag-SMN. This approach reduces potential
bias towards SMN partner proteins that may be more abundant in a
given tissue or cell line (Charroux et al., 1999; Meister et al., 2001;
Pellizzoni et al., 2002; Kroiss et al., 2008; Trinkle-Mulcahy et al., 2008;
Guruharsha et al., 2011). Here we identify the SCFSlmb E3 ubiquitin
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A previous study posited that a phosphodegron was specifically created by exon 7 skipping and that this event represented a key
aspect of the SMA disease mechanism (Cho
and Dreyfuss, 2010). Our identification of a
putative Slmb binding site located in the Cterminal self-oligomerization domain of
Drosophila and human SMN has allowed us
to explore the molecular details of this
hypothesis. The mutation of a conserved
serine within the Slmb degron not only disrupted the interaction between SMN and
Slmb but also stabilized full-length SMN
and SMN∆7. Notably, the degron mutation
has a greater effect on SMN levels (both fulllength and ∆7) when made in the context of
a protein that does not efficiently self-oligomerize. These and other findings strongly
suggest that the Slmb degron is uncovered
when SMN is monomeric, whereas it is less
accessible when SMN forms higher-order
multimers. On the basis of these results, we
conclude that SMN2 exon skipping does
not create a potent protein degradation
signal; rather, it exposes an existing one.

SMN targeting by multiple E2 and E3
systems

SMN degradation via the UPS is well established (Chang et al., 2004; Burnett et al.,
2009; Kwon et al., 2011). Using candidate approaches, investigators have studied
other E3 ligases that have been reported to
target SMN for degradation in cultured human cells (Hsu et al., 2010; Kwon et al.,
2013; Han et al., 2016). Given our findings,
it is therefore likely that SMN is targeted by
multiple E3 ubiquitin ligases, as this regulatory paradigm has been demonstrated for
a number of proteins (e.g., p53; Jain and
Barton, 2010). Targeting of a single protein
by multiple E3 ligases is thought to provide
regulatory specificity by expressing the
appropriate degradation complexes only within certain tissues, subcellular compartments, or developmental time frames. Moreover,
ubiquitylation does not always result in immediate destruction of
the target; differential use of ubiquitin lysine linkages or chain length
can alter a protein’s fate (Mukhopadhyay and Riezman, 2007; Ikeda
and Dikic, 2008; Liu and Walters, 2010).
Molecular Biology of the Cell

FIGURE 8: Proposed model of SMN as a substrate of SCFSlmb E3
ubiquitin ligase. Unstable SMN monomers, such as those created in
SMNΔ7, are the primary substrates for degradation. Active oligomers
of full-length SMN (SMN-FL) and partially active SMN-FL•SMN∆7
dimers (Praveen et al., 2014; Gupta et al., 2015) would be targeted to
a lesser extent. SCFSlmb is a multicomponent E3 ubiquitin ligase
composed of Slmb, SkpA, Cul1, and Roc1 (see the text for details).
This E3 ligase complex functions together with E1 and E2 proteins in
the ubiquitin proteasome system (UPS) to tag proteins for
degradation by linkage to ubiquitin (Ub). Phosphorylation (P) by
GSK3β and/or another kinase (see the text) is predicted to trigger
ubiquitylation.

FIGURE 7: SMN∆7A is a protective modifier of intermediate SMA
phenotypes in mice. (A) Mouse genotypes include control
unaffected Smn2B/+ mice, which have a wild-type Smn allele,
Smn2B/– (2B/–) mice treated with scAAV9 expressing different
versions of SMN, and untreated 2B/– mice, which are an
intermediate mouse model of SMA. 1e11 denotes the viral dose.
scAAV9-SMN expresses full-length SMN, scAAV9-SMNΔ7 expresses
truncated SMN, scAAV9-SMNΔ7S270A expresses truncated SMN with
the S-to-A change in the degron, and scAAV9-SMNΔ7S270D expresses
truncated SMN with a phosphomimic in the degron. Delivery of
AAV9-SMNΔ7A at P1 significantly extended survival in the
intermediate 2B/– animals, resulting in 100% of the treated pups
living beyond 100 d, similar to the results obtained with the
full-length AAV9-SMN construct. Untreated 2B/– animals lived, on
average, only 30 d. Mice treated with AAV9-SMNΔ7S survived an
average of 45 d. Mice treated with AAV9 expressing SMNΔ7D had
an average life span equivalent or slightly worse than that of
untreated 2B/– mice. (B) Average weight (measured over time) of
the animals used in panel A. AAV9-SMNΔ7A treated mice also
gained significantly more weight than either untreated or AAVSMNΔ7S-treated animals, nearly achieving the same weight as
2B/– pups treated with full-length SMN cDNA. (C) Mouse genotypes
include control unaffected Smn2B/+ mice, which carry a wild-type
Smn allele, and 2B/– mice treated with scAAV9 expressing different
versions of SMN. scAAV9-SMN expresses full-length SMN and
scAAV9-SMNΔ7S270A expresses truncated SMN with the S-to-A
change in the degron. AAV-SMNΔ7A-treated animals retained their
improved strength and gross motor functions at late time points
(P100), as measured by their ability to splay their legs and maintain
a hanging position using a modified tube test.
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Avenues of future exploration include determination of the E2
proteins that partner with SCFSlmb as well as the types of ubiquitin
lysine chain linkages they add to SMN. These two questions are interconnected, as ubiquitin linkage specificity is determined by the
E2 (Ye and Rape, 2009). Lysine 48 (K48) linked chains typically result
in degradation of the targeted protein by the 26S proteasome,
whereas lysine 63 (K63) linkage is more commonly associated with
lysosomal degradation and nonproteolytic functions such as endocytosis (Tan et al., 2008; Kirkin et al., 2009; Lim and Lim, 2011). Interestingly, recent work has implicated defects in endocytosis in SMA
(Custer and Androphy, 2014; Dimitriadi et al., 2016; Hosseinibarkooie et al., 2016). It remains to be determined how the ubiquitylation status of SMN might intersect with endocytic functions.

Does SMN function as a signaling hub?
In the Flag-SMN pull down, we identified three E2 proteins as potential SMN interacting partners (Figure 1C). Among them, Bendless (Ben) is particularly interesting. Ben physically interacts with
TRAF6, an E3 ligase that functions together with Ube2N/Ubc13/Ben
in human cells (Kim and Choi, 2017). TRAF6 is an activator of NF-kB
signaling, and its interaction with SMN is thought to inhibit this activity (Kim and Choi, 2017). Notably, Ube2N/Ben heterodimerizes
with Uev1a to form K63 ubiquitin linkages on target proteins (Ye and
Rape, 2009; van Wijk and Timmers, 2010; Komander and Rape,
2012; Marblestone et al., 2013; Zhang et al., 2013). Furthermore,
Ben-Uev1a is involved in upstream activation of both JNK (Jun
Nuclear Kinase) and IMD (Immune Deficiency) signaling in
Drosophila (Zhou et al., 2005; Paquette et al., 2010). Previously, we
and others have shown that JNK signaling is dysregulated in animal
models of SMA (Garcia et al., 2013, 2016; Genabai et al., 2015;
Ahmad et al., 2016). Moreover, mutations in all three components of
SCFSlmb lead to constitutive expression of antimicrobial peptides,
which are also downstream of the IMD pathway (Khush et al., 2002).
Together, these findings suggest the interesting possibility of SMN
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functioning as a signaling hub that links the UPS to the JNK and IMD
pathways, all of which have been shown to be disrupted in SMA.

of the amino acid changes detailed in Figure 4. Y203C, G206S, and
G210V were previously published in Praveen et al., 2014.

Phosphorylation of the Slmb degron within SMN

Drosophila embryo protein lysate and mass spectrometry

As Slmb is known to recognize phospho-degrons, one of the first
questions raised by our study concerns the identity of the kinase(s)
responsible for phosphorylating the degron in SMN. A prime candidate is GSK3β (Figure 8), as this kinase recognizes a motif (SxxxS/T;
Liu et al., 2007; Lee et al., 2013) that includes the degron and extends N-terminally (262SxxxSxxxSxxxT274, numbering as per human
SMN). In support of this hypothesis, we identified the Drosophila
GSK3β orthologue, Shaggy (Sgg), in our SMN pull downs (Figure
1C). Moreover, GSK3β inhibitors as well as siRNA-mediated knockdown of GSK3β were shown to increase SMN levels, primarily by
stabilizing the protein (Makhortova et al., 2011; Chen et al., 2012).
Finally, GSK3β is also responsible for phosphorylation of a degron in
β-catenin, a well-characterized SCFSlmb substrate (Liu et al., 2002).
SMA mice have low levels of UBA1 (E1), ultimately leading to accumulation of β-catenin (Wishart et al., 2014). Pharmacological inhibition of β-catenin improved neuromuscular pathology in Drosophila,
zebrafish, and mouse SMA models. β-Catenin had previously been
shown to regulate motor neuron differentiation and stability by
affecting synaptic structure and function (Murase et al., 2002; Li
et al., 2008; Ojeda et al., 2011). β-Catenin also regulates motor
neuron differentiation by retrograde signaling from skeletal muscle
(Li et al., 2008). The connections of UBA1 and multiple SCFSlmb substrates to motor neuron health thus places the UPS at the center of
SMA research interest.

Drosophila embryos (0–12 h) were collected from Oregon-R control
and Flag-SMN flies, dechorionated, flash frozen, and stored at –80°C.
Embryos (approximately 1 g) were then homogenized on ice with a
Potter tissue grinder in 5 ml of lysis buffer containing 100 mM potassium acetate, 30 mM HEPES–KOH at pH 7.4, 2 mM magnesium
acetate, 5 mM dithiothreitol (DTT), and protease inhibitor cocktail.
Lysates were centrifuged twice at 20,000 rpm for 20 min at 4°C and
dialyzed for 5 h at 4°C in Buffer D (HEPES 20 mM, pH 7.9, 100 mM
KCl, 2.5 mM MgCl2, 20% glycerol, 0.5 mM DTT, phenylmethylsulfonyl
fluoride [PMSF] 0.2 mM). Lysates were clarified again by centrifugation at 20,000 rpm for 20 min at 4°C. Lysates were flash frozen using
liquid nitrogen and stored at –80°C before use. Lysates were then
thawed on ice, centrifuged at 20,000 rpm for 20 min at 4°C and incubated with rotation with 100 μl of EZview Red Anti-FLAG M2 affinity
gel (Sigma) for 2 h at 4°C. Beads were washed a total of six times using buffer with KCl concentrations ranging from 100 to 250 mM with
rotation for 1 min at 4°C in between each wash. Finally, Flag proteins
were eluted 3 consecutive times with one bed volume of elution buffer (Tris 20 mM, pH 8, 100 mM KCl, 10% glycerol, 0.5 mM DTT, PMSF
0.2 mM) containing 250 μg/ml 3XFLAG peptide (sigma). The entire
eluate was used for mass spectrometry analysis on an Orbitrap Velos
instrument, fitted with a Thermo Easy-spray 50-cm column.

Concluding remarks
In summary, this study identifies conserved factors that regulate
SMN stability. To our knowledge, this work represents the first time
that SMN complexes have been purified in the context of an intact
developing organism. Using this approach, we have demonstrated
that the SCFSlmb E3 ligase complex interacts with a degron embedded within the self-oligomerization domain of SMN. Our findings
establish plausible connections to disease-relevant cellular processes and signaling pathways. Further, they elucidate a model
(Figure 8) whereby accessibility of the SMN phosphodegron is regulated by self-multimerization, providing an elegant mechanism for
balancing functional activity with degradation.

MATERIALS AND METHODS
Fly stocks and transgenes
Oregon-R was used as the wild-type control. The SmnX7 microdeletion allele (Chang et al., 2008) was a gift from S. Artavanis-Tsakonis
(Harvard University, Cambridge, MA). This deficiency removes the
promoter and the entire SMN coding region, leaving only the final
44 base pairs of the 3′ untranslated region (UTR). All stocks were
cultured on molasses and agar at room temperature (24 ± 1°C) in
half-pint bottles. The Smn transgenic constructs were injected into
embryos by BestGene (Chino Hills, CA) as described in Praveen
et al., 2014. In short, a ∼3 kb fragment containing the entire Smn
coding region was cloned from the Drosophila genome into the
pAttB vector (Bischof et al., 2007). A 3X FLAG tag was inserted immediately downstream of the start codon of dSMN. Point mutations
were introduced into this construct using Q5 (NEB) site-directed
mutagenesis according to manufacturer’s instructions. The basal
Smn construct used, vSmn, contained three single-amino-acid
changes, and the addition of the MGLR motif to make fruit fly Smn
more similar to the evolutionarily conserved vertebrate Smn. Subsequently generated constructs used vSmn as a template and consist
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Tissue culture and transfections
S2 cell lines were obtained from the Drosophila Genome Resource
Center (Bloomington, IL). S2 cells were maintained in SF900 serumfree medium (SFM) (Life Technologies) supplemented with 1% penicillin/streptomycin and filter sterilized. Cells were removed from the
flask using a cell scraper and passaged to maintain a density of
∼106–107 cells/ml. S2 cells were transferred to filter sterilized SF900
SFM (Life Technologies) without antibiotics prior to transfection with
Cellfectin II (Invitrogen). Transfections were performed according to
Cellfectin II protocol in a final volume of 4 ml in a T-25 flask containing 107 cells that were plated 1 h before transfection. The total
amount of DNA used in transfections was 2.5 μg. Human embryonic
kidney HEK-293T and HeLa cells were maintained at 37°C with 5%
CO2 in DMEM (Life Technologies) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Life Technologies).
Cells (1 × 106–2 × 106) were plated in T-25 flasks and transiently
transfected with 1–2 μg of plasmid DNA per flask using Lipofectamine (Invitrogen) or FuGENE HD transfection reagent (Roche
Applied Science, Indianapolis, IN) according to the manufacturer’s
protocol. Cells were harvested 24–72 h posttransfection.
For siRNA transections, HeLa cells were plated subconfluently in
T-25 flasks and transfected with 10 nm of siRNA (gift from Mike
Emanuele lab) and 17 μl Lipofectamine RNAi MAX (Invitrogen) in
5 ml total media according to manufacturer’s instructions. After 48 h
of transfection, cells were harvested. For RNAi in S2 cells using
dsRNA, 107 cells were plated in each well of a six-well plate in 1 ml
of media. Cells were treated approximately every 24 h with 10 μg/
ml dsRNA targeted against Slmb, Oskar, or Gaussia Luciferaese (as
controls) as described in Rogers and Rogers, 2008.

In vitro binding assay
GST and GST-SMN were purified from Escherichia coli. In brief, cells
transformed with BL21*GST-SMN were grown at 37°C overnight
and then induced using 1 mM isopropyl-β-d-thiogalactopyrano
side (IPTG). Recombinant protein was extracted and purified using
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glutathione sepharose 4B beads. GST-B-TrCP1 was purchased from
Novus Biologicals (cat# H00008945). SMN•Gem2 complexes were
coexpressed in E. coli using SMN∆5 and Gemin2(12–280) constructs, as described in Gupta et al. (2015). Glutathione sepharose
4B beads were washed 3× with phosphate-buffered saline (PBS).
GST alone, GST-SMN, or GST-B-TrCP1 were attached to beads during 4-h-overnight incubation at 4°C in PBS with rotation. Beads were
then washed 3× with modified radioimmunoprecipitation assay
(RIPA) buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM EDTA,
1% NP-40). Beads (20 μl) with ∼2 μg attached GST-tagged protein
(as determined by Coomassie stain with bovine serum albumin
[BSA] standard) were added to 200 μl modified RIPA buffer with
100 μg/ml BSA block. SMN•Gem2 (2 μg) was added, and the mixture was rotated end over end at 4°C overnight. Beads were then
washed 3× with modified RIPA buffer, and 10 μl SDS loading buffer
was added followed by boiling for 5 min.

In vivo ubiquitylation assay
The in vivo ubiquitylation assay was performed as described previously (Choudhury et al., 2016). Briefly, HEK-293T cells were transfected as indicated in 10-cm dishes using Lipofectamine2000
(Thermo Fisher Scientific). The day after, cells were treated with
20 µM of MG132 for 4 h and then harvested in PBS. Of the cell suspension, 80% was lysed in 6 M guanidine-HCl–containing buffer and
used to pull down His-Ubiquitinated proteins on Ni2+-NTA beads,
while the remaining 20% was used to prepare inputs. Ni2+ pulldown eluates and inputs were separated through SDS–PAGE and
analyzed by Western blot.

Cycloheximide treatment
Following RNAi treatment, S2 cells were pooled, centrifuged, and
resuspended in fresh media. One-third of these cells were frozen
and taken as the 0 h time point. The remainders of the cells were
replated in six-well plates. Cycloheximide (CHX; 100 μg/ml) was
added to each sample, and cells were harvested at 2 and 6 h
following treatment.

Immunoprecipitation
Clarified cell lysates were precleared with immunoglobulin G agarose beads for 1 h at 4°C and again precleared overnight at 4°C.
The precleared lysates were then incubated with anti-FLAG antibody cross-linked to agarose beads (EZview Red Anti-FLAG M2 affinity gel, Sigma) for 2 h at 4°C with rotation. The beads were washed
with lysis buffer or modified lysis buffer six times and boiled in SDS
gel-loading buffer. Eluted proteins were run on an SDS–PAGE for
Western blotting.

Antibodies and Western blotting
Larval and adult lysates were prepared by crushing the animals in
lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
NP-40) with 1× (adults) or 10× (larvae) protease inhibitor cocktail
(Invitrogen) and clearing the lysate by centrifugation at 13,000 rpm
for 10 min at 4°C. S2 cell lysates were prepared by suspending cells
in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1% NP-40) with 10% glycerol and 1× protease inhibitor cocktail (Invitrogen) and disrupting cell membranes by pulling the suspension
through a 25-gauge needle (Becton Dickinson). The lysate was then
cleared by centrifugation at 13,000 rpm for 10 min at 4°C. Human
cells (293T and HeLa) were first gently washed in ice-cold 1× PBS and
then collected in ice-cold 1× PBS by scraping. Cells were pelleted by
spinning at 1000 rpm for 5 min. The supernatant was removed,
and cells were resuspended in ice-cold lysis buffer (50 mM Tris-HCl,
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pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40) and allowed to lyse
on ice for 30 min. After lysing, the lysate was cleared by centrifuging
the cells for 10 min at 13,000 rpm at 4°C. Western blotting on lysates
was performed using standard protocols. Rabbit anti-dSMN serum
was generated by injecting rabbits with purified full-length dSMN
protein (Pacific Immunology Corp.) and was subsequently affinity
purified. For Western blotting, dilutions of 1 in 2500 for the affinity
purified anti-dSMN, 1 in 20,000 (fly) or 1 in 5000 (human) for anti–αtubulin (Sigma), 1 in 10,000 for monoclonal anti-Flag (Sigma), 1 in
1000 for anti-Slmb (gift from Greg Rogers, University of Arizona), 1 in
2500 for anti-human SMN (BD Biosciences), 1 in 1000 for anti–B-TrCP
(gift from Ben Major, University of North Carolina, Chapel Hill), 1 in
10,000 for polyclonal anti-Myc (Santa Cruz), and 1 in 2000 for antiGST (Abcam) were used.

Larval locomotion
Smn control and mutant larvae (73–77 h post–egg laying) were
placed on a 1.5% agarose molasses tray five at a time. The tray was
then placed in a box with a camera, and the larvae were recorded
moving freely for 60 s. Each set of larvae was recorded three times,
and one video was chosen for analysis based on video quality. The
videos were then converted to AVI files and analyzed using the
wrMTrck plug-in of the Fiji software. The “Body Lengths per Second” was calculated in wrMTrck by dividing the track length by half
the perimeter and time (seconds). p Values were generated using a
multiple comparison analysis of variance (ANOVA).

SMA mouse models
Two previously developed SMA mouse models were utilized. The
“Delta7” mouse (Smn−/−;SMN2;SMNΔ7) is a model of severe SMA
(Le et al., 2005). The “2B/–“ mouse (Smn2B/–) is a model of intermediate SMA (Bowerman et al., 2012; Rindt et al., 2015). Adeno-associated virus serotype 9 (AAV9) delivered SMN cDNA isoforms to
these SMA mice, as previously described (Foust et al., 2010; Passini
et al., 2010; Valori et al., 2010; Dominguez et al., 2011; Glascock
et al., 2012). Gross motor function was measured using a modified
tube test which tests the ability of mice to splay their legs and
maintain a hanging position.

Human iPSC cell culture
Human iPSCs from two independent unaffected control and two
SMA patient lines were grown as pluripotent colonies on Matrigel
substrate (Corning) in Nutristem medium (Stemgent). Colonies
were then lifted using 1 mg/ml Dispase (Life Technologies) and
maintained as floating spheres of neural progenitor cells in the neural progenitor growth medium Stemline (Sigma) supplemented with
100 ng/ml human basic fibroblast growth factor (FGF-2; Miltenyi),
100 ng/ml epidermal growth factor (EGF; Miltenyi), and 5 μg/ml
heparin (Sigma-Aldrich) in ultra-low attachment flasks. Aggregates
were passaged using a manual chopping technique as previously
described (Svendsen et al., 1998; Ebert et al., 2013). To induce motor neuron differentiation, neural progenitor cells were cultured in
neural induction medium (1:1 DMEM/F12 [Life Technologies], 1×
N2 Supplement [Life Technologies], 5 μg/ml Heparin [Sigma], 1×
Non-Essential Amino Acids [Life Technologies], and 1× AntibioticAntimycotic [Life Technologies]) plus 0.1 μM all-trans retinoic acid
(RA) for 2 wk; 1 μM Purmorphamine (PMN; Stemgent) was added
during the second week. Spheres were then dissociated with TrypLE
Express (Life Technologies) and plated onto Matrigel-coated 12mm coverslips in neural induction medium (NIM) plus 1 μM RA, 1
μM PMN, 1× B27 Supplement (Life Technologies), 200 ng/ml
ascorbic acid (Sigma), 1 μM cAMP (Sigma), 10 ng/ml brain-derived
SCFSlmb mediates degradation of SMN

| 107

neurotrophic factor (BDNF; Peprotech), and 10 ng/ml glial cell
line–derived neurotrophic factor (GDNF; Peprotech). One week
postplating, cells were infected with lentiviral vectors (multiplicity of
infection = 5) expressing mCherry alone or SMN S270A-IRESmCherry. Transgenes in both viruses were under the control of the
EF1α promoter. Uninfected cells served as controls. Cells were analyzed at 1 and 3 wk postinfection, which was 4 and 6 wk of total
differentiation (Ebert et al., 2009; Sareen et al., 2013).

Immunocytochemistry
Coverslips were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 20 min at room temperature and rinsed with PBS.
Cells were blocked with 5% normal donkey serum (Millipore) and
permeabilized in 0.2% Triton X-100 (Sigma) for 30 min at room temperature. Cells were then incubated in primary antibody solution for
1 h, rinsed with PBS and incubated in secondary antibody solution
for 1 h at room temperature. Finally, nuclei were labeled with
Hoechst nuclear stain (Sigma) to label DNA and mounted onto glass
slides using FluoroMount medium (SouthernBiotech). Primary antibodies used were mouse anti–SMI-32 (Covance SMI-32R; 1:1000)
and rabbit anti-mCherry (ThermoFisher; 1:1000). Secondary antibodies used were donkey anti-rabbit Cy3 (Jackson Immunoresearch
711–165–152) and donkey anti-mouse AF488 (Invitrogen A21202).

Immunocytochemical analysis
Images were acquired from five random fields per coverslip using an
inverted fluorescent microscope (Nikon) and NIS Elements software.
Images were blinded and manually analyzed for antigen specificity
with NIS Elements software.
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